semaglutide coming off market India could soon get a lot thinner - at least in theory., On Friday, the patent on - the molecule behind Danish drugmaker Novo Nordisk’s blockbuster weight-loss drugs Wegovy and Ozempic Hims is in the crosshairs.

TRIUMPH-3 also tracked cardiovascular events, but the results (hazard ratios of 1.12 and 0.82 for two different event composites) were not statistically significant meaning this trial cannot confirm cardiovascular benefit

Attorneys say the short-form complaint process was outlined to streamline documentation for plaintiffs, and the Rule 702 hearing date is confirmed for May 14, 2025

If youre not feeling up for much, try sitting comfortably and watching TV, listening to a podcast, or reading a book

Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis

It can boost metabolism, enhance endurance, and promote overall well-being without harmful effects